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Abstract
Background and Aims—Colonoscopy provides incomplete protection from colorectal cancer 
(CRC), but determinants of post-colonoscopy CRC are not well understood. We compared clinical 
features and molecular characteristics of CRCs diagnosed at different time intervals after a 
previous colonoscopy.
Methods—We performed a population-based, cross-sectional study of incident CRC cases in 
Denmark (2007–2011), categorized as post-colonoscopy or detected during diagnostic 
colonoscopy (in patients with no prior colonoscopy). We compared prevalence of proximal 
location and DNA mismatch repair deficiency (dMMR) in CRC tumors, relative to time since 
previous colonoscopy, using logistic regression and cubic splines to assess temporal variation.
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Results—Of 10,365 incident CRCs, 725 occurred after colonoscopy examinations (7.0%). These 
were more often located in the proximal colon (odds ratio [OR], 2.34; 95% CI, 1.90–2.89) and 
were more likely to have dMMR (OR, 1.26; 95% CI, 1.00–1.59), but were less likely to be 
metastatic at presentation (OR, 0.65; 95% CI, 0.48–0.89) compared with CRCs diagnosed in 
patients with no prior colonoscopy. The highest proportions of proximal and/or dMMR tumors 
were observed in CRCs diagnosed 3–6 years after colonoscopy, but these features were still more 
frequent among cancers diagnosed up to 10 years after colonoscopy. The relative excess of dMMR 
tumors was most pronounced in distal cancers. In an analysis of 85 cases detected after 
colonoscopy, we found BRAF mutations in 23% of tumors and that 7% of cases had features of 
Lynch syndrome. Colonoscopy exams were incomplete in a higher proportion of cases diagnosed 
within less than 1 year (in 38%) than in those diagnosed within 1–10 years after colonoscopy 
(16%).
Conclusion—In a study of incident CRC cases in Denmark, we observed that tumors found in 
patients who have undergone colonoscopy are more often proximal and have dMMR, compared to 
CRCs detected in patients without previous colonoscopies. The excess of right-sided tumors and 
the modest independent effects of dMMR reinforce the importance of proper colonoscopic 
examination of the proximal large bowel.
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Introduction
Colonoscopy with polypectomy reduces risk of subsequent colorectal cancer (CRC), and a 
negative examination portends a reduced risk as well.1,2 However, CRC diagnoses following 
a negative or clearing colonoscopy suggest that the protective effect of colonoscopy is 
weaker than originally estimated.3-8 Understanding how these cancers occur would inform 
interventions to optimize colonoscopy for CRC screening and prevention.
Colonoscopy quality is clearly implicated in post-colonoscopy or “interval” CRC, since risk 
has been associated with both endoscopist characteristics (e.g. specialty training and 
adenoma detection rates)6,9 and indicators of examination quality (e.g. preparation quality 
and completeness of examination).10,11 In addition, certain clinical characteristics have been 
found to be more common among post-colonoscopy CRCs, including older age at diagnosis, 
proximal tumor location, family history of CRC, and prior polypectomy.7,12,13 To date only 
a few studies have investigated the molecular characteristics of post-colonoscopy tumors, 
finding a relatively high prevalence of DNA microsatellite instability (MSI),5,14,15 CpG 
island methylator phenotypes (CIMP),16 and somatic BRAF mutations.17
Published data regarding molecular characteristics of post-colonoscopy CRC leave several 
questions unanswered, since relevant studies were not population-based and included only 
limited numbers of cases (167 in total).5,14-17 To date, all investigations have examined 
CRCs diagnosed at arbitrary intervals (e.g. 5 or 10 years) after colonoscopy, with little 
attention to possible interplay among molecular characteristics of post-colonoscopy cancers 
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and clinical factors. The independent associations of each characteristic with risk of cancer 
at different time intervals after colonoscopy remain unclear.
To examine the clinical and molecular features of post-colonoscopy CRC, we conducted a 
population-based study comparing clinical characteristics, tumor location, and mismatch 
repair deficiency (dMMR) between cases diagnosed at first colonoscopy and those 
diagnosed at different time intervals after a colonoscopy. We also conducted a detailed 
analysis of the molecular characteristics of a subset of post-colonoscopy CRC cases and the 
quality of the colonoscopy that preceded them.
Methods
Study design
Using Danish medical registries, we conducted a population-based nationwide study of all 
CRCs diagnosed during 2007-2011. We subsequently characterized subjects with incident 
CRC as “diagnostic colonoscopy only” if their only prior colonoscopic exam was within 180 
days of CRC diagnosis, or post-colonoscopy if they had at least 1 prior colonoscopy >180 
days prior to diagnosis. The latest colonoscopy performed >180 days prior to CRC diagnosis 
was defined as the “index” examination.
Databases
Each Danish resident is assigned a unique civil registration number, facilitating linkage of 
individual-level data among registries.18 The Danish National Patient Registry (DNPR) has 
recorded all inpatient hospital encounters since 1977 as well as outpatient hospital 
encounters since 1995,19 covering essentially all colonoscopy in the country.20 The Danish 
Cancer Registry (DCR) records all incident cancers diagnosed nationwide, coded using the 
International Classification of Diseases, Tenth Revision (ICD-10 version), with diagnosis 
date, tumor location, and stage.21 The National Pathology Registry archives pathology 
results from all specimens examined since 1997, using International Systematized 
Nomenclature of Medicine (SNOMED) codes.22
Nationwide incident CRC cases
We queried the DCR to identify all individuals newly diagnosed with CRC during the 5-year 
study period. Their records were linked to the DNPR to identify individuals who underwent 
one or more colonoscopies before their CRC diagnosis. We defined post-colonoscopy cases 
as those with one or more examinations >180 days prior to their CRC diagnosis in order to 
minimize contamination with diagnostic examinations, as individual chart reviews were not 
performed in the nationwide analysis.
Data abstracted included demographics, tumor location (classified as proximal: cecum 
through transverse colon; distal: splenic flexure through rectum; or unspecified), CRC stage 
at diagnosis (classified as localized, regional, metastatic, or unknown), histopathologic 
features, history of inflammatory bowel disease (IBD), and tumor DNA mismatch repair 
(MMR) protein expression. Testing for dMMR has been performed routinely as part of the 
clinical histopathologic evaluation of CRC resection specimens since 2007, with results 
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recorded in the Pathology Registry. Chart reviews conducted among the 19 Danish 
pathology institutes demonstrated that 12 had recorded dMMR status for >75% of CRC 
cases, whereas 7 recorded results less consistently (range: 0-64% of cases). To minimize 
potential bias, we restricted our study population to CRC cases evaluated at the 12 institutes 
performing dMMR testing regularly, representing 69% of CRC cases nationwide (Figure 1). 
dMMR status in CRC was assessed on the basis of immunohistochemistry (IHC) for MMR 
proteins with MLH1 and MSH2 in all cases, and for MSH6 and PMS2 in 74% and 45% of 
cases, respectively. Tumors exhibiting absent expression of one or more MMR proteins were 
classified as having dMMR and therefore microsatellite instability (MSI).
Hospital-based subset of Post-colonoscopy cases
Using the DCR, we ascertained CRC cases diagnosed at Aalborg University Hospital, 
serving a population of approximately 640,000. We identified 101 candidate post-
colonoscopy cases identified >90 days after colonoscopy, with available endoscopic records 
and formalin-fixed paraffin-embedded tumor blocks. Medical records were reviewed to 
confirm post-colonoscopy status. The latest colonoscopy performed >90 days prior to CRC 
diagnosis was defined as the “index” examination. After record reviews, 16 (16%) cases 
were excluded: the index exam was flexible sigmoidoscopy, not colonoscopy (n=5); the 
CRC diagnosis was known at the time (or within 90 days) of the index colonoscopy (n=7); 
or pathology review did not confirm colorectal adenocarcinoma (n=4). Eighty-five post-
colonoscopy CRC tumors remained for molecular analysis. Colonoscopy reports were 
abstracted to determine indication, bowel preparation quality, completeness of examination, 
findings including polyps (histology, number, and location), and polypectomy technique. 
Advanced adenomas were defined as those ≥10mm in size, and/or with high-grade dysplasia 
or villous histology.
An expert gastrointestinal pathologist (SRH) reviewed slides recut from the CRC tumor 
blocks without access to clinical information. For each tumor, nuclear expression of four 
DNA MMR proteins (MLH1, MSH2, MSH6, and PMS2) was evaluated by IHC.23,24 DNA 
extracted from microdissected cancer tissue was evaluated for somatic mutations in BRAF 
(V600E), KRAS (codons 12,13, 61, and 146), NRAS (codons 12,13), and PIK3CA (exons 9 
and 20) using Sequenom MassARRAY methodology.25,26
CRCs demonstrating absent nuclear expression of one or more MMR proteins were 
characterized as dMMR. Cases with equivocal IHC status were investigated using PCR 
amplification of a DNA microsatellite marker panel (BAT-25, BAT-26, BAT-40, TGFbRII, 
D2S123, D5S345, and D17S250).27 dMMR tumors were further characterized as “sporadic” 
or “Lynch syndrome” using current diagnostic algorithms.28 Tumors with loss of MLH1 
protein on IHC with BRAF gene mutation were classified as sporadic. Tumors with loss of 
MLH1 protein without BRAF mutation were studied further for MLH1 promoter 
hypermethylation using pyrosequencing.29 Tumors with loss of MLH1 protein without 
BRAF mutation or MLH1 promoter hypermethylation, and those showing loss of both 
MSH2 and MSH6 proteins, or MSH6 or PMS2 proteins only, were classified as consistent 
with Lynch syndrome.
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Statistical Analysis
In the nationwide analysis, we used standard descriptive statistics, t-tests, and contingency 
table analyses to examine differences between clinical and molecular features of diagnostic 
colonoscopy and post-colonoscopy CRC cases diagnosed at various intervals after the index 
colonoscopy. For dichotomous risk factors, we used restricted cubic splines30 (knots at 1, 3, 
6, 9, and 12 years) to assess variation in the post-colonoscopy:diagnostic prevalence ratio 
over time, adjusted for age at CRC diagnosis and gender (age only in analyses of gender). 
We visually estimated the duration of time that the post-colonoscopy:diagnostic differences 
persisted after the index colonoscopy, and the period during which they were greatest. 
Subsequently, we used logistic regression to compute odds ratios (ORs) and 95% confidence 
limits (CIs) to evaluate the associations between patient and tumor characteristics and post-
colonoscopy vs. diagnostic status within the selected time periods after the index 
colonoscopy. As index colonoscopy exams were performed at >70 endoscopy centers, we 
grouped CRC cases into 12 study centers corresponding to the regional pathology institutes 
serving each center as a proxy to adjust for potential differences by hospital. Interactions 
were assessed using Wald tests. Models included age, sex, site of cancer (proximal vs. 
distal), MMR status (deficient vs. proficient), and stage (metastatic vs. not metastatic), with 
adjustment for hospital. Goodness of fit for the logistic regression models was assessed 
using the Hosmer Lemeshow test10. To assess the impact of our definition of diagnostic 
CRC, we performed a sensitivity analysis extending the definition of diagnostic CRC cases 
to include those diagnosed within 90 days following the index colonoscopy.
For post-colonoscopy cases from the hospital sample, we used descriptive statistics to 
characterize patient and index procedure factors and tumor molecular characteristics among 
CRC cases diagnosed <1 year, 1 - 10 years, and >10 years following their index 
colonoscopy. Proportions were compared with Fisher's exact tests.
Analyses were conducted using SAS statistical software (version 9.3 SAS Institute, Cary, 
North Carolina). This study was approved by the Danish Data Protection Agency 
(2011-41-5913), the Danish Ethics Board (M-20110163), and the Institutional Review Board 
of the University of Texas MD Anderson Cancer Center.
Results
Analysis of Nationwide Sample
In the national sample 10,365 incident CRC cases were identified during the study period at 
the pathology institutes included in the study: 725 (7%) post-colonoscopy cases and 9,640 
(93%) diagnostic CRC cases (Table 1). Sixty eight (9%) post-colonoscopy cases were 
diagnosed within the first year after the index colonoscopy, 373 (51%) in the first 5 years, 
566 (78%) in the first 10 years, and 159 (22%) more than 10 years later. Post-colonoscopy 
cases were older than diagnostic CRC cases and included a higher proportion of individuals 
with IBD (Table 1, p<0.001). However, there were no substantial differences by gender. 
Post-colonoscopy tumors were more often proximal and more often diagnosed at localized 
stages (p<0.001).
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Tumor MMR testing was available for 8,965 (86%) CRC cases in the study population; 
1,565 (17%) were dMMR; of these, 1,350 (86%) exhibited loss of MLH1 expression, and 
844 (5.4%) loss of MSH2, MSH6, or PMS2 proteins. The prevalence of dMMR tumors was 
higher among post-colonoscopy than diagnostic cases in all the follow-up periods studied, 
across all clinical sites (Table 1, Supplementary Figure 1). Including CRCs diagnosed > 90 
days (rather than >180 days) after the index colonoscopy in the post-colonoscopy case 
definition did not change these results (Supplementary Table 1).
Compared to diagnostic cases, post-colonoscopy cancers were more often proximal and 
dMMR for up to 10 years after the index examination. The prevalence of these subtypes was 
highest among post-colonoscopy patients diagnosed 3-6 years after their index 
colonoscopies (Supplementary Figure 1).
During the 3-6 years following the index colonoscopy, when post-colonoscopy and 
diagnostic cases differed most, post-colonoscopy tumors were more likely to be located in 
the proximal colon [OR: 1.92 (95% CI 1.36, 2.72)] and to have evidence of dMMR [OR: 
1.53 (95% CI 1.06, 2.23)]. Older age and earlier stage were also independently associated 
with post-colonoscopy tumor status (Table 2). After adjustment for age and sex, dMMR was 
not independently associated with post-colonoscopy status in the proximal colon [OR: 1.40 
(95% CI 0.91, 2.14)], but approached statistical significance among the small numbers of 
distal tumors [OR 2.08 (95% CI 1.01, 4.26); p for interaction = 0.41] (Table 2). There were 
broadly similar findings for post-colonoscopy cases during the entire 10 year period during 
which the post-colonoscopy cases differed from the diagnostic cases (Table 2, Figure 2). 
Results were similar when using a more sensitive definition of post-colonoscopy cases 
diagnosed >90 days to 10 years after the index examination (data not shown).
Analysis of hospital-based subset of post-colonoscopy cases
The 85 post-colonoscopy cases were similar to the nationwide post-colonoscopy cases in 
age, gender, cancer stage, tumor location, and time between index colonoscopy and CRC 
diagnosis (Supplementary Table 2). The most frequent indications for the index 
examinations were symptoms (49%), polyp follow up (26%), and history of colitis (9%). 
Adenomas had been found in 27 (31%) subjects including 26 with advanced adenomas. 
Overall, quality of bowel preparation was not reliably recorded; however 18 (21%) post-
colonoscopy cases had endoscopic reports from the index colonoscopy which noted that the 
exam was incomplete (specifically that the cecum was not reached), and this was more 
common in cases diagnosed at shorter intervals: 38% among those diagnosed in the first year 
following the index colonoscopy and 16% among those diagnosed 1 - 10 years after 
(p=0.07).
Overall, 20 (24%) post-colonoscopy tumors exhibited dMMR. In tumors diagnosed within 
10 years of the index examination, BRAF mutations were identified in 16 (19%) tumors (12 
were dMMR), KRAS/NRAS mutations in 23 (27%), and PIK3CA mutations in 16 (19%). A 
total of 6 (7%) tumors had molecular characteristics of Lynch syndrome (Figure 3). All 
Lynch syndrome cancers occurred within the first 10 years after index colonoscopy. Four 
post-colonoscopy cases (5%) occurring less than 10 years after the index colonoscopy had 
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synchronous primary CRCs, three of which exhibited dMMR with somatic BRAF 
mutations, which are features of the serrated pathway.31
Discussion
In this large population-based study of more than 700 CRC cases diagnosed 180 days to 20+ 
years after colonoscopy, we found that proximal location and dMMR were overrepresented 
among post-colonoscopy cancers diagnosed up to 10 years later. The characteristics of post-
colonoscopy cases varied over time, with the highest prevalence of proximal location and 
dMMR 3 to 6 years after the index colonoscopy. The relative excess of dMMR tumors was 
more pronounced among cancers located in the distal colon. The nationwide findings were 
confirmed in analyses of post-colonoscopy cancers diagnosed up to 10 years after 
colonoscopy at a single center. Of these, 24% were dMMR, with 7% exhibiting molecular 
features of Lynch syndrome.
Our findings agree with previous research showing that CRCs diagnosed within 3 or 5 years 
after colonoscopy are more likely to be located in the proximal colon and exhibit dMMR 
than those diagnosed without a previous colonoscopy.5,14,15 Although some studies have 
suggested that the risk of interval cancer may be higher for women than men,32 we found no 
gender differences during the overall 10 year follow-up period.
Molecular characteristics of post-colonoscopy CRC have not been as well investigated as 
clinical features. Ours is the first population-based study to incorporate molecular 
phenotypes. Previous investigations of post-colonoscopy cases that reported molecular 
features included a total of 167 tumors diagnosed within 5 years of a colonoscopy (with a 
maximum cohort size of 63),5,13-1617 in contrast to 725 included in our analysis (566 
diagnosed within 10 years). Our findings demonstrate once again that proximal tumors and 
dMMR tumors are overrepresented among post-colonoscopy CRC cases.13,325,14 Our large 
sample size allowed use of multivariable analyses to estimate the independent effects of 
tumor location and molecular characteristics. Proximal location and dMMR commonly 
occur together in sporadic colorectal cancer, and we were able to demonstrate that while the 
association of proximal location with post-colonoscopy CRC is clear, the independent effect 
of dMMR is mostly exhibited in the distal colorectum.
Our analysis of the 85 hospital-based post-colonoscopy cases provided an opportunity to 
examine colonoscopy quality and molecular characteristics of tumors in more detail. Our 
finding of incomplete index examinations in 38% of post-colonoscopy cases diagnosed 
within the first year following a colonoscopy suggests that exam quality is important, 
especially in diagnoses made soon after colonoscopy. While the majority of sporadic as well 
as post-colonoscopy tumors develop through the chromosomal instability pathway, our 
molecular analyses confirmed that dMMR tumors are overrepresented among post-
colonoscopy CRCs. Lynch syndrome-associated neoplasms arise through this mutator 
pathway and are known to progress rapidly to cancer (often within 3 years after 
colonoscopy).33,34 Interestingly, we did find that the prevalence of Lynch syndrome among 
post-colonoscopy cases (7%) was more than double the reported population prevalence of 
2-3%35 and these tumors represented 1/3rd of dMMR cases within 10 years of a prior 
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colonoscopy. We also found that 1 in 5 post-colonoscopy cases were BRAF-mutated, a 
feature of serrated pathway carcinogenesis.31 However, the lack of controls in this analysis 
makes these findings difficult to interpret.
A novel feature of our analysis is that we included post-colonoscopy CRCs diagnosed 
during a wide range of time intervals after index colonoscopy and found considerable 
heterogeneity in the proportions of post-colonoscopy cancers that were proximal and 
dMMR, depending on time since the index examination. Other strengths of this study 
include the large population-based sample with availability of data regarding MMR status. 
Our detailed review of medical records and tumors of a representative subset of post-
colonoscopy cancers corroborates the nationwide findings.
However, we acknowledge that our study has certain limitations. Quality of colonoscopy 
exams is a determinant of effectiveness in preventing CRC, and is impacted by the success 
of the patient's bowel cleanout as well as the expertise of the endoscopist. While 80% of 
colonoscopies in Denmark are performed by gastrointestinal specialists36, detailed data 
regarding endoscopist and procedure characteristics (eg. adenoma detection rate, withdrawal 
time, cleanliness) were not available for the nationwide cases and thus the quality of 
individual index colonoscopy exams could not be assessed. A number of reviews of 
outcomes of CRC screening exams performed in Denmark have reported 89-93% of 
colonoscopies are “complete” 36,3738 which is slightly below the quality benchmark of 95% 
cecal intubation rate, and lower than that reported in a European randomized clinical trial39. 
It is also worth noting that since colonoscopic screening for average risk individuals was not 
current practice in Denmark during the study period, most individuals who underwent 
colonoscopies had symptoms or previous polyps that prompted colonoscopic evaluation. 
Consequently, it is possible our findings may not be generalizable to populations in which 
high quality colonoscopy screening of asymptomatic average-risk individuals is more widely 
employed. We recognize that our analysis depends on the accuracy of our data. While the 
DCR offers near-complete ascertainment of cancer cases, it is possible that post-
colonoscopy and diagnostic CRC cases may have been misclassified, as occurred in 15% of 
post-colonoscopy cases reviewed in our hospital sample (10% in the national sample with 
the 180 day time window).
Our finding that 7% of CRC cases in Denmark occurred in individuals who had undergone a 
prior colonoscopy is a clinical and medicolegal concern. Our data imply that the problem of 
post-colonoscopy cancers, though greatest about 3-6 years following colonoscopy, persists 
to some extent far longer than the 5-year time frame commonly used to define so-called 
“interval” cancers. The high proportion of proximal tumors, in conjunction with the 
frequency of incomplete colonoscopy among post-colonoscopy cases diagnosed within the 
first year following colonoscopy, supports the popular assumption that many cancers 
diagnosed soon after colonoscopy result from missed lesions. 4036 However, the 
heterogeneity in clinical and molecular features of cancers diagnosed at different time 
intervals suggests post-colonoscopy CRCs are likely multifactorial in their etiology and 
clinical behavior. Studies consistently show that colonoscopy affords less protection against 
proximal cancers3,7,41,42 and dMMR tumors are more frequent among proximal cancers. 
The proximal and distal colon differ with respect to embryologic origin and gene expression 
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profiles, prompting some to suggest that these might be considered as two distinct organs.43 
Whether the precursors of post-colonoscopy CRCs are simply harder to detect and/or resect 
endoscopically, or whether their behavior differs on the basis of anatomic location and/or 
molecular subtype remains unclear and warrants further investigation. Our study adds to the 
literature supporting that a paramount concern is effective visualization of the proximal large 
bowel to maximize the effectiveness of colonoscopy.
Supplementary Material
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Figure 1. 
Flow chart of colorectal cancer (CRC) cases diagnosed nationwide in Denmark during 
2007-2011, showing post-colonoscopy (PC) vs. diagnostic colonoscopy (DC) cases, and a 
hospital-based subsample of PC cases.
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Figure 2. 
Restricted cubic spline analyses showing variation in the PC/DC prevalence ratio (PR) of 
patient and tumor characteristics over time since prior colonoscopy, adjusted for sex and age 
(PR= solid line, 95% CI=dashed lines)
(A) PR of proximal tumor location, (B) PR of mismatch repair deficiency (MMR)
Stoffel et al. Page 14
Gastroenterology. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PR of MMR stratified by tumor location proximal (C) and distal (D)
Splines have 5 knots at 1, 3, 6, 9 and 12 years.
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Figure 3. 
Distribution of molecular characteristics among hospital-based PC cases, by interval 
between colonoscopy and CRC diagnosis (n=85).
Note: Figures are not proportional between time intervals.
Area exterior to MSS circle represents MSI-high tumors.
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Table 2
Multivariate analysis of factors independently associated with post-colonoscopy colorectal cancer between 180 
days and 10 years after index colonoscopy (n = 566 PC cases).
Patient or tumor characteristic
PC cases 3 - 6 years 
mean ± SD or n (%)
PC cases 180 days - 
10 years mean ± SD 
or n (%)
3 - 6 years OR (95% 
CI)
180 days - 10 years OR 
(95% CI)
Age at CRC diagnosis (years) 73.2 ± 9.9 73.8 ± 10.3 1.02 (1.01, 1.04) 1.03 (1.02, 1.04)
Female sex 116 (59.8) 305 (53.9) 0.74 (0.54, 1.02) 0.91 (0.75, 1.10)
Proximal tumor location 104 (53.6) 306 (54.1) 1.92 (1.36, 2.72) 2.33 (1.89, 2.88)
Metastatic at presentation 21 (10.8) 62 (11.0) 0.68 (0.41, 1.13) 0.66 (0.48, 0.90)
Mismatch repair-deficient
 Overall 55 (28.4) 140 (24.7) 1.53 (1.06, 2.23) 1.28 (1.02, 1.62)
 Proximal 46 (23.7) 120 (21.2) 1.40 (0.91, 2.14) 1.18 (0.91, 1.54)
 Distal 9 (4.6) 20 (3.5) 2.08 (1.01, 4.26) 1.85 (1.14, 3.01)
Logistic regression modeling used to estimate odds ratios and 95% CI for post-colonoscopy cancer over specified time intervals, adjusting for age, 
age, sex, site of cancer (proximal vs. distal), MMR status (deficient vs. proficient), stage (metastatic vs. not metastatic), and clinical center
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